ARDENT HEALTH INC (ARDT) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:ARDT - US03980N1072 - Common Stock
8.79 USD
-0.08 (-0.9%)
8.741 USD
-0.05 (-0.56%)
ChartMill assigns a Buy % Consensus number of 80% to ARDT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.58. This target is 88.57% above the current price.
ARDT was analyzed by 19 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about ARDT.
In the previous month the buy percentage consensus was at a similar level.
ARDT was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-24 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-18 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-18 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-17 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2025-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-14 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-11-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-11-13 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-10-14 | Goldman Sachs | Initiate | Neutral |
| 2025-09-10 | UBS | Initiate | Buy |
| 2025-08-11 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-08-07 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-16 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2025-05-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-05-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-04-09 | Guggenheim | Initiate | Buy |
| 2025-04-01 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-26 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-02-27 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-21 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-01-06 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-12 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-11-06 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-10-11 | Keybanc | Initiate | Overweight |
| 2024-09-19 | Stephens & Co. | Reiterate | Overweight -> Overweight |
ARDENT HEALTH INC / ARDT FAQ
What do analysts expect the price target to be for ARDENT HEALTH INC (ARDT)?
19 analysts have analysed ARDT and the average price target is 16.58 USD. This implies a price increase of 88.57% is expected in the next year compared to the current price of 8.79.
What is the consensus rating for ARDT stock?
The consensus rating for ARDENT HEALTH INC (ARDT) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for ARDT stock?
The number of analysts covering ARDENT HEALTH INC (ARDT) is 19.